NCT05968599 2026-02-25
A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
Pfizer
Completed
Clinical Trials
88 trialsNCT01314118 2026-02-24
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Janssen Biotech, Inc.
Phase 2 Completed
NCT03565835 2026-01-26
Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer
Montefiore Medical Center
Phase 2 Completed
NCT06072196 2025-12-31
A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Pfizer
Completed
NCT05457257 2025-12-19
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
AstraZeneca
Phase 4 Completed
NCT03007732 2025-12-05
Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
University of California, San Francisco
Phase 2 Completed
NCT01961843 2025-11-25
Abiraterone Acetate for Castrate Resistant Prostate Cancer
Massachusetts General Hospital
Phase NA Completed
NCT04477512 2025-11-12
Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)
Washington University School of Medicine
Phase 1 Completed
NCT03098836 2025-09-12
PANTHER
Duke University
Phase 2 Completed
NCT03458247 2025-09-05
OPTIMABI
Assistance Publique - Hôpitaux de Paris
Phase 2 Completed
NCT04666129 2025-08-17
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT03568656 2025-08-08
Study to Evaluate CCS1477 in Advanced Tumours
CellCentric Ltd.
Phase 1/2 Completed
NCT03298087 2025-08-01
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
VA Office of Research and Development
Phase 2 Completed
NCT02903368 2025-06-13
Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy
Dana-Farber Cancer Institute
Phase 2 Completed
NCT06151418 2025-06-04
A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces
Pfizer
Completed
NCT03834519 2025-05-18
KEYLYNK-010
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01848067 2025-05-04
Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
Thomas Jefferson University
Phase 1/2 Completed
NCT02025010 2025-04-15
Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01792687 2025-03-04
Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate
Aragon Pharmaceuticals, Inc.
Phase 1 Completed
NCT01309672 2025-02-26
S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy
SWOG Cancer Research Network
Phase 2 Completed
NCT00887198 2025-02-04
Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Janssen Research & Development, LLC
Phase 3 Completed
NCT01715285 2025-02-04
A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
Janssen Research & Development, LLC
Phase 3 Completed
NCT04869488 2025-01-24
A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT01650194 2024-12-10
A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients
Astellas Pharma Inc
Phase 2 Completed
NCT02218606 2024-12-10
Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02366494 2024-11-25
Micro RNAs to Predict Response to Androgen Deprivation Therapy
Medical College of Wisconsin
Completed
NCT05520138 2024-09-27
Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)
Pfizer
Completed
NCT01685268 2024-08-02
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
Astex Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT02903160 2024-02-07
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT02543255 2024-01-31
ACDC-RP
University Health Network, Toronto
Phase 2 Completed
NCT04887506 2024-01-16
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
Tavanta Therapeutics
Phase 3 Completed
NCT02987543 2023-10-06
Study of Olaparib (Lynparzaâ„¢) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)
AstraZeneca
Phase 3 Completed
NCT01995513 2023-09-18
PLATO
Pfizer
Phase 4 Completed
NCT04628988 2023-09-13
A Study of CC-90011 and Comparators in Participants With Prostate Cancer
Celgene
Phase 1 Completed
NCT04179396 2023-06-29
RAMP
pharmaand GmbH
Phase 1 Completed
NCT03043807 2023-02-16
A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02789878 2022-09-15
Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer
Instituto do Cancer do Estado de São Paulo
Phase 2 Completed
NCT03279250 2022-08-10
Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02485691 2022-05-27
CARD
Sanofi
Phase 4 Completed
NCT01517802 2022-05-10
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
Janssen Research & Development, LLC
Phase 3 Completed
NCT02268175 2022-04-19
Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02849990 2022-01-13
A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy
University of Washington
Phase 2 Completed
NCT01751451 2021-11-19
3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02962284 2021-11-19
One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With YONSAâ„¢
Sun Pharmaceutical Industries Limited
Phase 2 Completed
NCT04071262 2021-09-21
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT01574937 2021-08-06
XL-184+Abiraterone in Post-Chemo CRPC
Dana-Farber Cancer Institute
Phase 1 Completed
NCT04889651 2021-07-22
A Study to Compare the Pharmacokinetics and Safety Between BR9004 and BR9004-1 in Healthy Male Volunteers
Boryung Pharmaceutical Co., Ltd
Phase 1 Completed
NCT01503229 2021-05-14
Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
University of Washington
Phase 2 Completed
NCT02867852 2021-03-03
SG-ABI14
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT01842321 2021-02-23
AMA
UNICANCER
Phase 2 Completed